Durham, North Carolina
Chute et al reported today that administration of mouse endothelial cells to irradiated B6 recipients was capable of accelerating hematopoietic reconstitution after sublethal and lethal irradiation.
In a paper entitled "Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice" published in today's electronic version of the journal Blood, the investigators noted that while both brain-derived and fetal blood derived primary endothelial cells were capable of accelerating hematopoiesis, the brain derived cells had superior activity.
It appears that this paper supports the work behind US patent #6642049 which covers in claim 1:
...expanding human bone marrow CD34+CD38- hematopoietic progenitor cells, including primitive stem cells, in vitro, comprising the steps of: i) isolating and culturing human brain endothelial cells by dissecting segments of blood vessels from the Circle of Willis; ii) contacting isolated CD34+CD38- hematopoietic progenitor cells with the isolated and cultured human brain endothelial cells; and iii) co-culturing the contacted CD34+CD38- hematopoietic progenitor cells and endothelial cells in the presence of at least one cytokine in an amount sufficient to support amplification/expansion of said CD34+CD38- hemratopoietic progenitor cells.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.